MacroGenics, Inc. (NASDAQ:MGNX) Position Increased by Marshall Wace LLP

Marshall Wace LLP increased its holdings in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 1,689.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 658,007 shares of the biopharmaceutical company's stock after purchasing an additional 621,232 shares during the period. Marshall Wace LLP owned approximately 1.05% of MacroGenics worth $2,797,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. ProShare Advisors LLC boosted its stake in shares of MacroGenics by 8.9% during the first quarter. ProShare Advisors LLC now owns 15,282 shares of the biopharmaceutical company's stock valued at $225,000 after purchasing an additional 1,246 shares during the period. Diversified Trust Co boosted its stake in MacroGenics by 16.0% in the 1st quarter. Diversified Trust Co now owns 13,630 shares of the biopharmaceutical company's stock worth $201,000 after purchasing an additional 1,880 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of MacroGenics during the first quarter valued at $40,000. CANADA LIFE ASSURANCE Co acquired a new position in shares of MacroGenics in the first quarter valued at about $52,000. Finally, Principal Financial Group Inc. raised its position in MacroGenics by 1.1% during the 2nd quarter. Principal Financial Group Inc. now owns 348,421 shares of the biopharmaceutical company's stock worth $1,481,000 after buying an additional 3,818 shares during the last quarter. Hedge funds and other institutional investors own 96.89% of the company's stock.

MacroGenics Stock Up 1.7 %

Shares of MacroGenics stock traded up $0.06 during mid-day trading on Friday, reaching $3.61. 280,345 shares of the stock traded hands, compared to its average volume of 1,589,297. The stock has a market capitalization of $226.11 million, a PE ratio of -9.03 and a beta of 2.08. The business has a 50-day moving average of $3.55 and a 200 day moving average of $7.22. MacroGenics, Inc. has a fifty-two week low of $2.95 and a fifty-two week high of $21.88.

MacroGenics (NASDAQ:MGNX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.42). MacroGenics had a negative net margin of 332.47% and a negative return on equity of 146.01%. The firm had revenue of $10.80 million during the quarter, compared to analysts' expectations of $24.14 million. On average, equities research analysts expect that MacroGenics, Inc. will post -1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on MGNX shares. HC Wainwright reiterated a "neutral" rating and set a $4.00 price objective on shares of MacroGenics in a research note on Wednesday, September 18th. Evercore ISI raised shares of MacroGenics to a "strong-buy" rating in a report on Monday, September 16th. JMP Securities decreased their price objective on shares of MacroGenics from $16.00 to $8.00 and set a "market outperform" rating for the company in a research report on Wednesday, July 31st. Citigroup dropped their target price on MacroGenics from $16.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, August 15th. Finally, StockNews.com lowered MacroGenics from a "hold" rating to a "sell" rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $8.11.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.